INTERNATIONAL
SPECIALIST EYE CENTRE MALAYSIA
国际眼科中心
An affiliated teaching institute of Faculty of Allied Health Sciences, UKM
An affiliated partner of CIBA VISION Academy for eye care excellence
A Joint Commission
International (JCI)
Accredited
Healthcare Facility
Home    
Text Size  
 
Cornea & Anterior Segment
 
 
Cornea Collagen Cross-Linking ( C3R / CXL):
Advanced Treatment for Keratoconus at ISEC®
 

Many Cornea Specialists are now using Corneal Collagen Cross linking with Riboflavin (C3R or CXL) as a treatment for patients with keratoconus. Recent evidence and studies have shown that Corneal Collagen Cross linking with Riboflavin (CXL) strengthens the corneal structure and can help prevent the progression of keratoconus and other conditions that weaken the cornea (ectasia) .

CXL works by increasing collagen cross linking, giving the cornea greater ability to withstand degeneration that occurs in diseases such as keratoconus. The CXL treated and strengthened cornea thus is protected against the progressive bulging and steepening seen in advanced keratoconus.

Corneal Cross Linking with Riboflavin is now performed at many of the top refractive eye clinics in Europe, Asia, and North America. During this advanced treatment, sterile riboflavin drops are applied to the surface of the cornea. These drops will absorb into the cornea and are used to trigger the cross linking inside the corneal stroma. The riboflavin drops are activated by exposure to low doses of ultraviolet light under carefully measured treatments by the corneal specialist. Clinical studies are showing that CXL treatment increases the amount of collagen cross-linking in the cornea in order to strengthen the cornea. In studies at clinics in Europe, Asia, and America, CXL treatments were demonstrated to be both safe and effective for keratoconus patients.

CXL treatment could also be a treatment option for a rare complication of LASIK known as corneal ectasia. This complication occurs in less than 1 in 10,000 treatments and has become even rarer with advances in LASIK treatments.

In summary, corneal collagen cross linking has been used to stop the progression of keratoconus and may reduce the need for penetrating keratoplasty or cornea transplantation. Progressive corneal ectasia includes primary keratoconus, keratoconus after corneal refractive surgery and pellucid marginal degeneration. In these conditions, the corneal stroma is structurally weakened and biomechanically unstable. CXL has been shown to improve the biomechanical properties of the cornea. In fact, corneal stiffness has been shown to increase by 300% in some of these experiments.

 
 
At ISEC, we have been performing CXL treatments successfully on a regular basis for a large number of keratoconus patients since 2008, using the state of the art custom UVX- machine from Switzerland, developed by the father of CXL, Prof Dr Theo Seiler of Germany. The treatment process takes approximately 1 to 1.5 hour per eye, and is relatively painless, although some discomfort is to be expected for the first few days after the procedure.
 
 
A Joint Commission
International (JCI)
Accredited
Healthcare Facility
  Links   Print   Add to Favourite   Tell Your Friends   Site Map
KKLIU 0017/2015 | Copyright © 2015 ISEC Sdn. Bhd | Web Design by Webz